NCT01316887 - A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

563

Participants

Timeline

Start Date

January 1, 2011

Primary Completion Date

July 1, 2012

Study Completion Date

July 21, 2012

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

125/25 mcg once-daily GSK573719/GW642444

GSK573719/GW642444

DRUG

125mcg once-daily GSK573719

GSK573719

DRUG

Placebo once-daily

inactive

Trial Locations (54)

1501

GSK Investigational Site, Benoni

4001

GSK Investigational Site, Durban

7130

GSK Investigational Site, Somerset West

7505

GSK Investigational Site, Tygerberg

7530

GSK Investigational Site, Bellville

7700

GSK Investigational Site, Mowbray

7764

GSK Investigational Site, Gatesville

9301

GSK Investigational Site, Bloemfontein

16508

GSK Investigational Site, Erie

23229

GSK Investigational Site, Richmond

26505

GSK Investigational Site, Morgantown

28207

GSK Investigational Site, Charlotte

29303

GSK Investigational Site, Spartanburg

29379

GSK Investigational Site, Union

36608

GSK Investigational Site, Mobile

43215

GSK Investigational Site, Columbus

55441

GSK Investigational Site, Plymouth

63141

GSK Investigational Site, St Louis

70000

GSK Investigational Site, Bucharest

70584

GSK Investigational Site, Sunset

73103

GSK Investigational Site, Oklahoma City

75110

GSK Investigational Site, Corsicana

78229

GSK Investigational Site, San Antonio

100172

GSK Investigational Site, Ploieşti

100379

GSK Investigational Site, Ploieşti

110084

GSK Investigational Site, Piteşti

127018

GSK Investigational Site, Moscow

153005

GSK Investigational Site, Ivanovo

173008

GSK Investigational Site, Veliky Novgorod

193231

GSK Investigational Site, Saint Petersburg

194354

GSK Investigational Site, Saint Petersburg

197706

GSK Investigational Site, St'Petersburg

300310

GSK Investigational Site, Timișoara

346510

GSK Investigational Site, Shakhty, Rostov Region

354057

GSK Investigational Site, Sochi

440067

GSK Investigational Site, Penza

500112

GSK Investigational Site, Brasov

500283

GSK Investigational Site, Brasov

600252

GSK Investigational Site, Bacau

620109

GSK Investigational Site, Yekaterinburg

625023

GSK Investigational Site, Tyumen

690950

GSK Investigational Site, Vladivostok

3460001

GSK Investigational Site, Talca

8207257

GSK Investigational Site, Puente Alto - Santiago

8380453

GSK Investigational Site, Santiago

29406-7108

GSK Investigational Site, Charleston

119 048

GSK Investigational Site, Moscow

634 050

GSK Investigational Site, Tomsk

826 06

GSK Investigational Site, Bratislava

841 08

GSK Investigational Site, Bratislava

058 01

GSK Investigational Site, Poprad

017 26

GSK Investigational Site, Považská Bystrica

927 01

GSK Investigational Site, Šaľa

012 07

GSK Investigational Site, Žilina